High Dose Versus Routine Dose Icotinib in Pretreated Non-small Cell Lung Cancer Patients With Stable Disease: a Phase II Randomized Study
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2019
Price : $35 *
At a glance
- Drugs Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Betta Pharmaceuticals Co Ltd
- 21 May 2015 Planned End Date changed from 1 May 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
- 21 May 2015 Planned primary completion date changed from 1 Jan 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
- 15 Jan 2014 New trial record